Odyssey Therapeutics Announces $218 Million Series A Financing To Advance Next Generation Inflammation And Oncology Medicines
Dec 07, 2021•over 3 years ago
Amount Raised
$218 Million
Round Type
series a
Description
Odyssey Therapeutics, a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the completion of an oversubscribed $218 million Series A financing led by OrbiMed Advisors and co-led by SR One Capital Management with participation from Foresite Capital, Woodline Partners LP, Logos Capital, HBM Healthcare Investments, Colt Ventures, Creacion Ventures, and other institutional investors. Carl L. Gordon, Ph.D., Managing Partner of OrbiMed Advisors, will join Odyssey's board of directors. The financing will be used to advance multiple pipeline programs and Odyssey's discovery platform aimed at expanding the druggable genome
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech